Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet

Tuberculosis Clinical Trial

Official title:

Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03800381
• Other study ID #: IRB201801820 - HRZ PK -N
• Secondary ID: 5R01HD071779-11
• Status: Recruiting
• Start date: January 28, 2019
• Est. completion date: August 31, 2024

Study information

• Verified date: May 2024
• Source: University of Florida
• Contact: Awewura Kwara, MD
• Phone: 3522739501
• Email: awewura.kwara[@]medicine.ufl.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lack of quality-assured pediatric formulations of the first-line antituberculosis (anti-TB) drugs is barrier to optimized tuberculosis (TB) treatment outcome in children. In 2010 and subsequently modified in 2014, the World Health Organization (WHO) recommended increased dosages of the first-line anti-TB drugs for children, but there were no child-friendly fixed-dose combination (FDC) formulations based on the guidelines. A large proportion of children treated with the new guidelines using old formulations did not achieve the desired rifampin peak concentration (Cmax) > 8 mg/L and pyrazinamide Cmax > 35 mg/L. The TB Alliance and the WHO led the development of a new child-appropriate isoniazid/rifampin/pyrazinamide (HRZ) and isoniazid/rifampin (HR) FDC formulation in line with current WHO recommended dosing guidelines. The new formulations dissolve quickly in liquid, have palatable fruit flavors, and are expected to improved daily adherence but no studies have evaluated the pharmacokinetics (PK) of the FDC formulation in children. The study team hypothesize that the new dispersible HRZ FDC tablet, dosed according to current WHO weight-band dosing recommendations will result in better PK parameters for each drug component than that achieved by the old formulation.

Description:

This study will evaluate the PK of the new pediatric HRZ FDC tablet in Ghanaian children with TB with and without HIV coinfection. The new HRZ FDC dispersible tablet was designed to be child-friendly and to achieve recommended dosages for each weight-band. The formulation has been rolled out in Africa without PK studies in the target population to verify that the tablets achieves adequate drug concentrations. The current study will evaluate the adequacy of the formulation by examining the PK of the component drugs as well as the effect of HIV coinfection. The direct PK data will be used in a population PK model and stimulations to define optimal weight-band dosages and proportions of the components of the pediatric FDC tablets.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 92
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Months to 14 Years

Eligibility

Inclusion Criteria:

• Children with active TB with or without HIV coinfection. Active TB diagnosis defined by clinical criteria consistent with active TB and/or a positive AFB smear.

• Available for follow-up until completion of TB treatment and/or achievement of a study endpoint like discontinuation of therapy, and/or pharmacokinetic sampling.

Exclusion Criteria:

• Children with concurrent conditions other than HIV, have acute hepatitis within 30 days of study entry, persistent vomiting, and diarrhea will be excluded from the study.

• Unable to obtain informed signed consent from parent(s) or legal guardian.

• Have AIDS-related opportunistic infections other than TB, history of or proven acute hepatitis within 30 days of study entry, persistent vomiting, or diarrhea.

• Hemoglobin < 6 g/dl, white blood cells < 2500/mm3, serum creatinine > 1.5 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) > 2 times upper limit of normal.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Coinfection
• HIV Infections
• Human Immunodeficiency Virus
• Tuberculosis

Intervention

Other:
• Observational PK study
The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.

Locations

Country	Name	City	State
Ghana	Kwame Nkrumah University of Science and Technology	Kumasi

Sponsors (2)

Lead Sponsor	Collaborator
University of Florida	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

Ghana, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak concentration (Cmax) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.	Mean and median Cmax of rifampin, isoniazid and pyrazinamide in children with TB treated with the new HRZ FDC tablet.	After at least 4 weeks of anti-TB therapy
Primary	Area under the time-concentration curve from 0-8 hours (AUC0-8h) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.	Mean and median AUC0-8h of rifampin, isoniazid and pyrazinamide in children with TB treated with the new HRZ FDC tablet.	After at least 4 weeks of anti-TB therapy
Primary	Cmax of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection	Geometric mean values of Cmax of rifampin, isoniazid and pyrazinamide in children with HIV/TB coinfection compared to those with TB alone.	After at least 4 weeks of anti-TB therapy
Primary	AUC0-8h of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection.	Geometric mean values of AUC0-8h of rifampin, isoniazid and pyrazinamide in children with HIV/TB coinfection compared to those with TB alone.	After at least 4 weeks of anti-TB therapy
Secondary	AUC0-8h of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.	Geometric mean values of AUC0-8h of rifampin, isoniazid, and pyrazinamide in children with TB treated with the new FDC tablet compared to those treated with the old formulation in our previous study (historical controls).	After at least 4 weeks of anti-TB therapy
Secondary	Cmax of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.	Geometric mean values of Cmax of rifampin, isoniazid, and pyrazinamide in children with TB treated with the new FDC tablet compared to those treated with the old formulation in our previous study (historical controls).	After at least 4 weeks of anti-TB therapy
Secondary	Proportion of children treated with new pediatric HRZ FDC tablet who develop with liver enzymes elevations.	Frequency of liver enzymes elevations compared to baseline requiring treatment modification in children with TB with and without HIV coinfection.	After at least 4 weeks of anti-TB therapy
Secondary	Identify optimal weight-band dosages of the new HRZ FDC tablet	Use a population PK model that incorporates demographic, clinical and genetic factors and stimulations to identify the optimal weight-band dosing of the new FDC formulation.	After at least 4 weeks of anti-TB therapy